Acadia Pharma (ACAD) Tops Q4 EPS by 64c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $25.97 +3.06%
EPS Growth %: -62.5%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
CRMT, More
EPS Growth %: -62.5%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of $0.86, $0.64 better than the analyst estimate of $0.22. Revenue for the quarter came in at $259.6 million versus the consensus estimate of $271.64 million.
GUIDANCE:
Acadia Pharma sees FY2025 revenue of $1.03-1.09 billion, versus the consensus of $1.05 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Acadia Pharmaceuticals (ACAD) PT Raised to $36 at Canaccord
- Raymond James Upgrades Aecon Group (ARE:CN) (AEGXF) to Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
